Form 4: Foghorn Therapeutics Director Stuart Duty Acquires 50,000 Stock Options

Director Stuart Duty acquired 50,000 stock options in Foghorn Therapeutics Inc. on May 1, 2025.

Summary

• On May 1, 2025, Stuart Duty, a director of Foghorn Therapeutics Inc., acquired 50,000 stock options.
• The exercise price of these options is $4.16.
• The options vest in three equal installments on the first three anniversaries of the grant date, contingent upon continued service on the board of directors.
• The expiration date for these options is April 30, 2035.
• Following the transaction, Duty beneficially owns 50,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants to a director, which doesn't inherently indicate positive or negative news.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities by a company insider. Such filings are common and provide transparency to the market regarding insider transactions.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates a director's increased stake in the company.

Key Dates

Keywords

Stock Options, Form 4, Director, Beneficial Ownership, Foghorn Therapeutics, FHTX, Duty